MARK NAVARRO: Open Payments
NPI 1356992614 · VICTORVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,651 in 14 payments from 10 companies in 2025. Trend: 2023 $250 · 2024 $1,124 · 2025 $1,651
Food & beverage: $1,651
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 4 | $573 |
| GENZYME CORPORATION | 2 | $250 |
| Regeneron Healthcare Solutions, Inc. | 1 | $135 |
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| GlaxoSmithKline, LLC. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Verona Pharma, Inc. | 1 | $125 |
| Insmed, Inc. | 1 | $115 |
| Actelion Pharmaceuticals US, Inc. | 1 | $65 |
| ABBVIE INC. | 1 | $14 |
Products named: REZDIFFRA, DUPIXENT, AIRSUPRA, NUCALA, VOQUEZNA, Ohtuvayre, Arikayce, RINVOQ.
Industry payments across CA — which companies pay providers there.
